The University of Iowa is recruiting patients for participation “in a large multinational study testing Abciximab (ReoPro) in patients with acute ischemic stroke.”
Here’s a bit more about the study, excerpted from a News-Medical.net article.
Unlike other investigational treatments to open blocked arteries in stroke beyond three hours, abciximab can be given into a vein in the arm and requires no additional invasive procedures. “Abciximab has been used for years by cardiologists to help keep diseased coronary arteries open,” explains Dr. Bernstein. “If this treatment proves safe and effective in acute stroke, it could be used in any emergency room throughout the country. This could fundamentally change the way we treat this common and devastating disease.”
Participants are potentially eligible for this trial if they can receive study drug or placebo within 6 hours of stroke onset, or if they wake up from sleep with a stroke and can receive study drug or placebo within three hours of waking up.